

PREVALENCE OF MALARIAL PARASITE AND STUDY OF VARIOUS
BIOCHEMICAL AND HEMATOLOGICAL PARAMETERS BEFORE AND
AFTER TREATMENT IN POPULATION OF DISTRICT BANNU

Sadiq Shah

Department of Biochemistry, Hazara University Mansehra Pakistan

sadaq217@gmail.com

Muhammad Raza

Medical Lab Technology, Hazara University Mansehra Pakistan

razamuhammad819@gmail.com

Faiza Abdul Rehman

Department of Zoology, University of Lahore Sargodha Campus

faizarehman395@gmail.com

Pakeeza Saif

Department of Microbiology, Superior University of Lahore

023806pakeezasaif@gmail.com

Rubab Gull

Department of Zoology, University of Lahore Sargodha campus

rubabgull80@gmail.com

Sumbel Ayesha

Department of Microbiology, Abbottabad University of Science & Technology

6ayeshasumbel@gmail.com

Mohsin Hanif

Medical Lab Technology, Abbottabad university of Science & Technology

7mohsin.hanif012@gmail.com

Tufser Ur Rehman

Department of Medical Lab Technology, Abbottabad University of Science & Technology

8tufserurrehman131@gmail.com

Farman Ali

Department of Microbiology, Abbottabad University of Science & Technology

farman.faryal@gmail.com

Nodia Shujaat

Department of Biochemistry Hazara University Mansehra Pakistan

nodiabiochemistry@hu.edu.pk

Latif Ullah

Department of Nursing, Khyber Medical University Peshawar

latifullahswat44@gmail.com

Author Details**Keywords:**

Received on 03 Apr 2026

Accepted on 04 May 2026

Published on 30 May 2026

Corresponding E-mails & Authors*:

Farman Ali

farman.faryal@gmail.com,

Nodia Shujaat

nodiabiochemistry@hu.edu.pk**Abstract**

Malaria remains a major public health concern in Pakistan, with *Plasmodium vivax* predominating in most endemic areas. This study aimed to evaluate the prevalence of malaria and assess associated hematological, biochemical, and electrolyte alterations among patients in District Bannu, Khyber Pakhtunkhwa. A total of 2,500 blood samples were collected from clinically suspected cases and examined by both microscopy and rapid diagnostic tests (RDTs). All positive cases (100%) were identified as *P. vivax* monoinfections, with no detection of *P. falciparum* or mixed species. Hematological analysis revealed significant anemia (mean Hb: 9.0 g/dl), leucopenia (mean WBC: 4,100 cells/ml), and marked thrombocytopenia (mean platelets: 14,300 cells/mm²) prior to treatment, with partial recovery post-treatment. Biochemical profiling demonstrated hypoglycemia, hyperbilirubinemia, and dyslipidemia characterized by reduced total cholesterol, HDL, and LDL levels. Liver enzymes (ALT, AST) were mildly elevated, while electrolyte analysis indicated hyponatremia, hypokalemia, and hypocalcemia before treatment, with improvement following therapy. These findings highlight that *P. vivax* infection in the study area is associated with substantial hematological and metabolic disturbances, emphasizing the need for timely diagnosis, appropriate management, and strengthened malaria control strategies in endemic regions.

INTRODUCTION

Malaria is a vector-borne infectious disease caused by protozoan parasites of the genus *Plasmodium* that infect peripheral blood (1). It is not only one of the most prevalent tropical diseases worldwide but also poses a major threat to public health and the economic development of many countries (2).

Despite advancements in medical science, malaria remains a significant global health challenge, causing an estimated one million deaths annually (3). Over one billion people live in regions with a high risk of malaria transmission (4). In 2010, an estimated 3.3 billion people were at risk of malaria. Among all geographical regions, sub-Saharan Africa bears the highest burden, accounting for approximately 81% of malaria cases and 91% of related deaths in that year. Children under five years of age and pregnant women are the most severely affected (5). Malaria is more prevalent in rural areas, where access to healthcare is limited. As a result, many cases go undiagnosed and unreported, suggesting that the actual number of malaria patients may be significantly higher than documented (6).

Malaria is endemic in various regions of the world, including parts of the Americas, most of Asia, large areas of Africa, and especially regions located near the equator (7). In Pakistan, both *Plasmodium vivax* and *Plasmodium falciparum* are prevalent (8). According to the World Health Organization (9), approximately 97% of the Pakistani population around 150 million people is at risk of malaria, with an estimated annual burden of 1.6 million cases.

Malaria transmission in Pakistan is highly seasonal and prone to epidemic outbreaks in specific regions, particularly Khyber Pakhtunkhwa, Balochistan, and Sindh provinces. The peak transmission season typically occurs from September to November, following the monsoon rains. A secondary, shorter transmission period occurs in spring (March–April), though most of these cases are believed to be relapses or delayed presentations of *P. vivax* infections acquired during the monsoon season. *P. vivax* accounts for roughly 75% of malaria cases, while *P. falciparum* contributes around 25% (10). As a tropical and largely agricultural country with a majority of its population living in rural areas and below the poverty line, Pakistan is particularly vulnerable to malaria. Several factors contribute to the increasing incidence of malaria, including poverty, environmental degradation, and the widespread emergence of chloroquine-resistant *P. falciparum*. Additionally, warmer autumns that prolong the transmission period, reduced vector control efforts, extensive

irrigation systems, monsoon rainfall, and large-scale agricultural activities create ideal breeding conditions for malaria vectors (11).

Pakistan is considered hyperendemic for malaria; however, accurate and comprehensive data on its prevalence remain limited (12). While *Plasmodium vivax* remains the dominant species causing malaria in the country, the incidence of *P. falciparum* has been steadily increasing and now accounts for approximately 35–40% of malaria cases (13). Given this concerning trend, the present study was undertaken to evaluate the current malaria situation in the local population of Bannu District.

1. Materials and Methods

2.1. Description of the Study Area

The study was conducted in Bannu District (32°43'–33°06' N; 70°22'–70°57' E), located in Khyber Pakhtunkhwa (KPK), Pakistan (Fig. 1). The Kurram and Gambila rivers flow through the district, providing water for irrigation and unintentionally creating ideal breeding sites for malaria vectors. The mean daily temperature in the area ranges from 10.8°C to 32.9°C. Bannu experiences two distinct rainy seasons: one in March (spring) and the other during the summer monsoon period in July and August (Ministry of Health, Pakistan, 2010).



Fig. 1. Map of Pakistan showing the study area in Khyber Pakhtunkhwa

2.2. Sample Collection

A total of 2500 blood samples were collected from suspected malaria patients visiting DHQ hospital Bannu and other local healthcare facilities across various areas of District Bannu. The study population included 1920 males and 580 females, reflecting a higher incidence of malaria in the male population. Blood samples were obtained through venipuncture using sterile techniques and were immediately transferred to EDTA and plain tubes for hematological and biochemical analyses, respectively. In addition, blood films were prepared on clean glass slides, air-dried, and stained using standard Giemsa staining protocol for microscopic identification of malarial parasites. All sample collections were carried out following standard biosafety protocols, and informed verbal consent was obtained from the patients prior to collection.

2.3. Microscopic Examination and Hematological Analysis

For microscopic diagnosis of malaria, both thick and thin blood films were prepared from each patient sample. The thin smears were fixed with absolute methanol for 30 seconds after air-drying. All smears were stained using freshly prepared 10% Giemsa stain, prepared by mixing 1 ml of stock solution with 9 ml of phosphate buffer (pH 7.2). After staining, the slides were gently rinsed with tap water and allowed to dry in an upright position. The prepared slides were then examined under a light microscope using a 100× oil immersion objective lenses. For quality assurance, each new batch of Giemsa stain was validated using a positive control smear. Parasite density was assessed by counting the number of parasites per thick film field, and all smears were double-checked independently. Smears were considered negative only when no parasites were detected across 100 high-power fields.

In addition to microscopy, hematological parameters were evaluated using the ERBA XL-200 Hematology Analyzer. EDTA-treated blood samples were gently mixed on a rotator for 10–15 minutes to ensure homogeneity. The samples were then aspirated into the analyzer via a sample probe, and results were displayed within 20 seconds. A complete blood count (CBC) was performed

using fresh blood to measure critical indicators such as hemoglobin concentration, total leukocyte count (TLC), and platelet count. Normal reference ranges were as follows: hemoglobin - 13 to 18 g/dL for males and 11 to 16 g/dL for females; TLC - 4,000 to 11,000 cells/cmm; and platelet count - 150,000 to 450,000 cells/cmm.

2.4. Biochemical and Electrolyte Analysis

Biochemical and electrolyte parameters of the blood samples were assessed using standard clinical laboratory procedures and automated analyzers. Blood was collected in clot-activator tubes, and serum was separated by centrifugation. The serum was then subjected to biochemical analysis using an Automated Chemistry Analyzer (Microlab 300 LX), which measured levels of liver enzymes (ALT and AST), bilirubin, cholesterol, HDL, LDL, and glucose. Reagents and calibrators were used according to the manufacturer's instructions, and absorbance readings were obtained spectrophotometrically. For liver function assessment, ALT and AST were analyzed using reagent mixtures with appropriate serum volumes, and results were interpreted using reference ranges of up to 42 U/L for ALT and 40 U/L for AST. Total bilirubin was determined through sequential reagent addition followed by incubation, with a normal reference range of 0.2–1.0 mg/dL. Cholesterol levels were estimated using enzymatic methods, with HDL and LDL measured directly through incubation of serum with respective reagents at 37°C, and values interpreted using standard clinical ranges. Random blood glucose (RBS) levels were analyzed by mixing serum with prepared reagent, incubating the mixture, and measuring absorbance after 10 minutes. Normal RBS and fasting blood glucose (FBS) ranges were considered as 80–140 mg/dL and 70–110 mg/dL, respectively. Electrolyte levels, including sodium, potassium, calcium, phosphate, and bicarbonate, were measured using a fully automated arterial blood gas (ABG) and electrolyte analyzer. The system required 200 µL of serum per test and provided results based on internal calibration. The following normal reference values were used for interpretation: sodium (135–145 mmol/L), potassium (3.6–5.0 mmol/L), calcium (8.6–10.2 mg/dL), phosphate (2.7–4.5 mg/dL in adults; 4.5–6.7 mg/dL in children), and

bicarbonate (22–28 mEq/L for arterial, 24–30 mEq/L for venous samples). All analyses were conducted in duplicate to ensure precision and reliability of results.

2. RESULTS

3.1. Prevalence of Malaria Parasite

Microscopic examination of 2,500 blood samples collected from malaria-infected individuals in District Bannu revealed that **100% of cases were positive for *Plasmodium vivax***. No cases of *P. falciparum* or mixed infections were detected in the study sample, confirming *P. vivax* as the dominant malarial species in the area.

3.2. Diagnostic Tools Performance

Both Rapid Diagnostic Tests (RDTs) and microscopic examination were used for parasite detection. All RDT-positive cases were confirmed by microscopy. However, in cases with low parasitemia, microscopy occasionally yielded false-negative results, indicating its reduced sensitivity at low parasite densities compared to RDTs.

3.3. Blood Glucose Levels

The mean blood glucose level in healthy individuals was **140 mg/dl**, whereas malaria patients had a significantly lower average of **68 mg/dl** before treatment. After treatment, the average blood glucose increased to **120 mg/dl**, approaching but still slightly below the normal range. This consistent hypoglycemia was observed across all age groups, even before the initiation of therapy.

3.4. Bilirubin Levels

Total serum bilirubin was markedly elevated in malaria patients, with an average of **5.0 mg/dl** before treatment compared to the normal average of **1.0 mg/dl**. After treatment, bilirubin levels decreased

substantially to 0.7 mg/dl, indicating recovery of liver function. The elevation was present even in patients infected solely with *P. vivax*.

3.5. Changes in Plasma Lipids and Lipoproteins

Total cholesterol levels were significantly reduced before treatment (85 mg/dl) compared to the normal average (200 mg/dl), consistent with hypocholesterolemia. Following treatment, cholesterol levels improved to 166 mg/dl but did not fully reach the normal range. HDL cholesterol decreased slightly from the normal 50 mg/dl to 44 mg/dl before treatment and improved to 49 mg/dl after treatment. LDL cholesterol showed a more pronounced decrease from the normal 150 mg/dl to 40 mg/dl before treatment, rising to 140 mg/dl post-treatment.

3.6. Liver Enzymes (ALT and AST)

Before treatment, AST levels averaged 53 u/L, slightly higher than the normal 40 u/L, and decreased to 46 u/L post-treatment. ALT levels were similarly elevated from a normal 45 IU/L to 55 IU/L before treatment, later declining to 49 IU/L after therapy. These mild increases suggest that malaria had a limited effect on liver enzyme levels in most patients.

3.7. Electrolyte Changes

Sodium levels dropped from the normal average of 145 mmol/L to 78 mmol/L before treatment, improving to 124 mmol/L after treatment, indicating a trend toward correction of hyponatremia. Potassium levels decreased from the normal 5.0 mmol/L to 2.3 mmol/L before treatment, later increasing to 4.2 mmol/L. Calcium levels were reduced from a normal 10 mg/dl to 6.2 mg/dl pre-treatment, rising to 9.0 mg/dl post-treatment. Plasma inorganic phosphate (PO₄) decreased from the normal 7.01 mg/L to 5.03 mg/L before treatment and further dropped to 4.04 mg/L after treatment. Bicarbonate (HCO₃⁻) levels fell from the normal 75 mEq/L to 30 mEq/L before

treatment and to 22 mEq/L after treatment, although the changes were not statistically significant in clinical terms.

3.8. Hematological Parameters

Hemoglobin levels averaged 9.0 g/dl before treatment compared to the normal 16 g/dl, later increasing to 11 g/dl after treatment, indicating anemia in most patients. White blood cell counts dropped from a normal 11,000 cells/ml to 4,100 cells/ml before treatment, improving to 5,700 cells/ml post-treatment, reflecting leucopenia in the majority of cases. Platelet counts showed severe thrombocytopenia, with pre-treatment averages of 14,300 cells/mm² compared to the normal 450,000 cells/mm². After treatment, platelet counts improved to 193,000 cells/mm², though still below normal in many patients.

Table.1. Blood parameters in Plasmodium Vivax before and after treatment.

Parameters	Patients	Normal Average level	Average lever before treatment	Average level after treatment
Blood glucose level (mg/dl)	2500	140	68	120
Bilirubin level (mg/dl)	2500	1	5	0.7
Cholesterol level (mg/dl)	2500	200	85	166
AST level (u/L)	2500	40	53	46
ALT level (IU/L)	2500	45	55	49
HDL level (mg/dl)	2500	50	44	49
LDL level (mg/dl)	2500	150	40	140
Na level (mmol/L)	2500	145	78	124
K level (mmol/L)	2500	5	2.3	4.2

Ca level(mg/dl)	2500	10	6.2	9
PO4 level (mg/L)	2500	7.01	5.03	4.04
HCO ₃ Level (mEq/L)	2500	75	30	22
Hb level (g/dl)	2500	16	9	11
WBCs level (cells/ml)	2500	11000	4100	5700
Platelets level (cells/mm ²)	2500	450000	14300	193000

4. Discussion

This study investigated the prevalence of malaria parasites and their effects on various biochemical and hematological parameters in the population of District Bannu, with measurements taken before and after treatment. The findings demonstrate that *Plasmodium vivax* was the sole and predominant malarial species in the area, affecting multiple physiological systems and producing measurable biochemical and hematological alterations. The observed changes highlight both the direct pathogenic effects of the parasite and the partial reversibility of these effects following antimalarial treatment. Microscopic examination of 2,500 samples confirmed *P. vivax* as the only species present, accounting for 100% of infections. This finding is in agreement with previous reports from other regions of Pakistan, where *P. vivax* is more prevalent than *P. falciparum*, especially in the northwestern belt (14). The absence of *P. falciparum* or mixed infections in this study may be related to ecological, climatic, or vector distribution factors specific to Bannu. Both microscopy and rapid diagnostic tests (RDTs) performed well in diagnosis; however, low-parasitemia cases occasionally produced false-negative microscopy results, confirming earlier observations that RDTs may have superior sensitivity in low-density infections (14).

A marked hypoglycemia was detected in malaria patients prior to treatment, with average blood glucose dropping from the normal 140 mg/dl to 68 mg/dl. This decrease can be attributed to increased glucose consumption by both host immune responses and the parasite itself, as *Plasmodium* relies heavily on host glucose for its energy metabolism (15). Even after treatment, glucose levels rose

only to 120 mg/dl, remaining slightly below normal, suggesting that recovery of metabolic balance may lag behind parasite clearance. Persistent mild hypoglycemia post-treatment could also be influenced by nutritional deficiencies or ongoing systemic inflammation. Bilirubin levels showed a dramatic rise from 1.0 mg/dl in healthy individuals to 5.0 mg/dl in infected patients, before decreasing to 0.7 mg/dl after therapy. This elevation likely results from increased hemolysis of parasitized red blood cells and impaired hepatic clearance of bilirubin during acute infection (16). The normalization of bilirubin after treatment indicates that liver function impairment in *P. vivax* malaria is generally reversible, though the transient hyperbilirubinemia may contribute to the clinical jaundice observed in some patients.

The study also confirmed the occurrence of malaria-associated hypocholesterolemia, with total cholesterol falling from 200 mg/dl to 85 mg/dl pre-treatment. LDL cholesterol showed a pronounced drop from 150 mg/dl to 40 mg/dl, while HDL declined modestly. After treatment, partial recovery was observed, but lipid levels did not fully return to normal. These findings are consistent with previous reports (17) attributing the changes to increased lipid utilization by the parasite for membrane synthesis during schizogony, as well as cytokine-mediated alterations in lipid metabolism. AST and ALT levels showed only mild elevation before treatment, with averages of 53 u/L and 55 IU/L, respectively, compared to normal values of 40 u/L and 45 IU/L. These changes were largely reversible, suggesting minimal hepatocellular injury in most *P. vivax* cases. Previous studies have also reported that liver enzyme elevations are more prominent in *P. falciparum* infections or in severe *P. vivax* malaria complicated by hepatic dysfunction (18).

Significant electrolyte imbalances were noted, including hyponatremia (78 mmol/L), hypokalemia (2.3 mmol/L), and hypocalcemia (6.2 mg/dl) before treatment. These abnormalities improved post-treatment but did not always return to normal ranges. Such changes may be due to increased renal losses, shifts between intracellular and extracellular compartments, and parasite-induced alterations in cell membrane transport. Interestingly, bicarbonate levels decreased both before and after treatment, though not to a clinically critical degree, suggesting possible persistent metabolic acid-

base imbalance. Hematological alterations were among the most profound findings. Anemia was highly prevalent, with hemoglobin levels dropping from 16 g/dl in healthy controls to 9 g/dl in infected patients, improving to 11 g/dl after treatment. The anemia likely results from a combination of hemolysis, splenic sequestration, and bone marrow suppression. Severe thrombocytopenia (14,300 cells/mm²) was common, with partial recovery post-treatment (193,000 cells/mm²). Leucopenia was also frequent, possibly reflecting bone marrow suppression or redistribution of leukocytes to the spleen and other tissues. These findings are consistent with previous studies identifying anemia and thrombocytopenia as hallmark hematological features of *P. vivax* malaria (19). The results indicate that *P. vivax* malaria, often considered less severe than *P. falciparum*, can produce significant biochemical and hematological abnormalities. Many parameters showed only partial normalization after treatment, highlighting the need for extended follow-up and supportive care beyond antimalarial therapy. Correcting nutritional deficiencies, monitoring liver function, and managing electrolyte imbalances should be integral to post-treatment recovery plans. A limitation of this study is that it focused solely on *P. vivax* cases in one district, which may not reflect parasite distribution in other regions of Pakistan. Longitudinal studies with larger geographic coverage could better assess seasonal and regional variations. Additionally, including follow-up measurements beyond the immediate post-treatment phase would clarify the timeline for complete biochemical and hematological recovery.

3. Conclusion

This study confirms *Plasmodium vivax* as the sole malarial species prevalent in District Bannu. Malaria significantly impacted multiple biochemical and hematological parameters, including marked hypoglycemia, hyperbilirubinemia, hypocholesterolemia, electrolyte imbalances, anemia, leucopenia, and severe thrombocytopenia. Post-treatment, most parameters showed substantial improvement, though several remained below normal ranges, indicating partial recovery and the need for continued monitoring. These findings highlight the systemic effects of *P. vivax* infection and

emphasize the importance of timely diagnosis, effective treatment, and post-therapy follow-up to ensure full physiological restoration.

4. References

- Gentry PR, Covington TR, Lawrence G, McDonald T, Snow ET, Germolec D, et al. Comparison of tissue dosimetry in the mouse following chronic exposure to arsenic compounds. *Journal of toxicology and environmental health Part A*. 2005;68(5):329-51.
- Garcia LS. Malaria. *Clinics in laboratory medicine*. 2010;30(1):93-129.
- Savi MK. An Overview of Malaria Transmission Mechanisms, Control, and Modeling. *Medical sciences (Basel, Switzerland)*. 2022;11(1).
- Escalante AA, Pacheco MA. Malaria Molecular Epidemiology: An Evolutionary Genetics Perspective. *Microbiology spectrum*. 2019;7(4).
- Venkatesan P. The 2023 WHO World malaria report. *The Lancet Microbe*. 2024;5(3):e214.
- Poespoprodjo JR, Douglas NM, Ansong D, Kho S, Anstey NM. Malaria. *Lancet (London, England)*. 2023;402(10419):2328-45.
- Adkins S, Lamb EM, Roberts PD, Gooch MD, Breman L, Shuler KD. Identification of Pepper mild mottle virus in Commercial Bell Pepper in Florida. *Plant disease*. 2001;85(6):679.
- Martínez-Ruiz C, Black JRM, Puttick C, Hill MS, Demeulemeester J, Larose Cadieux E, et al. Genomic-transcriptomic evolution in lung cancer and metastasis. *Nature*. 2023;616(7957):543-52.
- Pasquale H, Jarvese M, Julla A, Doggale C, Sebit B, Lual MY, et al. Malaria control in South Sudan, 2006-2013: strategies, progress and challenges. *Malaria journal*. 2013;12:374.
- Kocarnik JM, Compton K, Dean FE, Fu W, Gaw BL, Harvey JD, et al. Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019: A Systematic Analysis for the Global Burden of Disease Study 2019. *JAMA oncology*. 2022;8(3):420-44.

- Rab MA, Freeman TW, Durrani N, de Poerck D, Rowland MW. Resistance of Plasmodium falciparum malaria to chloroquine is widespread in eastern Afghanistan. *Annals of tropical medicine and parasitology*. 2001;95(1):41-6.
- Fatima SH, Zaidi F, Rafiq J, Bhandari D, Ali A, Bi P. Impact of temperatures on malaria incidence in vulnerable regions of Pakistan: empirical evidence and future projections. *Epidemiology and infection*. 2025;153:e33.
- Asif SA. Departmental audit of malaria control programme 2001-2005 north west frontier province (NWFP). *Journal of Ayub Medical College, Abbottabad : JAMC*. 2008;20(1):98-102.
- Moemenbellah-Fard MD, Saleh V, Banafshi O, Dabaghmanesh T. Malaria elimination trend from a hypo-endemic unstable active focus in southern Iran: predisposing climatic factors. *Pathogens and global health*. 2012;106(6):358-65.
- Ghanchi NK, Shakoor S, Thaver AM, Khan MS, Janjua A, Beg MA. Current situation and challenges in implementing Malaria control strategies in Pakistan. *Critical reviews in microbiology*. 2016;42(4):588-93.
- Vijayakumar S, Viswanathan S, Jain D. The Utility of Platelet Indices in Predicting Multiorgan Dysfunction in Scrub Typhus. *Interdisciplinary perspectives on infectious diseases*. 2020;2020:3870354.
- Arroyo V, Moreau R, Kamath PS, Jalan R, Ginès P, Nevens F, et al. Acute-on-chronic liver failure in cirrhosis. *Nature reviews Disease primers*. 2016;2:16041.
- Comesaña M, Ferré P, Romero J, Guasch M, Soares AP, García-Chico T. Facilitative effect of cognate words vanishes when reducing the orthographic overlap: The role of stimuli list composition. *Journal of experimental psychology Learning, memory, and cognition*. 2015;41(3):614-35.
- Khan T, Khan A, Khan A, Badshah F, Ibáñez-Arancibia E, De Los Ríos-Escalante PR, et al. Assessment of hematological parameters in malarial suspected patients: Cross sectional study. *Parasite epidemiology and control*. 2024;26:e00367.